The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
Scand J Gastroenterol
; 59(3): 269-279, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-37991266
ABSTRACT
BACKGROUND:
Therapeutic drug monitoring (TDM) plays a crucial role in the management of Crohn's disease (CD) patients receiving infliximab (IFX). While reactive TDM has been more commonly utilized previously, recent research suggests that proactive TDM may offer greater benefits for patients.OBJECTIVE:
To compare treatment outcomes among patients receiving different monitoring modalities of IFX.METHODS:
This was a retrospective cohort study that enrolled 142 CD patients who initiated IFX therapy at the First Affiliated Hospital of Nanjing Medical University from January 2014 to June 2021. The patients were divided into a reactive (n = 43) and proactive (n = 99) group. The outcome measures included sustained clinical response and remission rates, biological remission rates, endoscopic response and remission rates achieved in both groups at weeks 30 and 54. The incidence of adverse events (AEs), changes in IFX trough concentrations (TCs) and treatment adjustments within 54 weeks were also evaluated.RESULTS:
Kaplan-Meier analysis demonstrated that the proactive group exhibited significantly higher cumulative probabilities of sustained clinical response, sustained clinical remission, and endoscopic response by Week 54. Compared to the reactive group, patients in the proactive group achieved significantly reduced rates of AEs-related hospitalization and surgery. After adjusting treatment strategies, the median concentration and the proportion of patients achieved an effective therapeutic concentration (TC > 3 µg/mL) at Week 54 was both significantly higher in the proactive group.CONCLUSIONS:
Proactive TDM of IFX plays a more crucial role in timely adjustment of treatment strategies and maintenance of effective concentrations, thereby contributing to the outcomes for CD patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Gastrointestinais
/
Doença de Crohn
/
Monitoramento de Medicamentos
/
Infliximab
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article